Amphista Signs a License Agreement with BMS to Discover & Develop Targeted Protein Degradation Therapies Using Eclipsys TPD Platform
Shots:
- Amphista to receive a $30M up front & is eligible to receive ~$1.25B in performance-based milestones & additional fees for a limited expansion of the collaboration along with royalties on global net sales of the products
- BMS will get an exclusive license globally for the development of degraders and will be responsible for the development and commercialization activities
- The collaboration will use Amphista's Eclipsys targeted protein degradation platform to develop novel protein degrading therapies. The collaboration also combines BMS’ strong legacy and experience in the protein degradation to deliver new effective treatments to patients
Ref: PRNewswire | Image: Amphista
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
